This phase I trial tests the safety, side effects, and best dose of curcumin in HIV patients with abnormal (precancerous) anal lesions living with HIV. The use of curcumin, the yellow pigment in the spice turmeric, may prevent anal cancer from forming in HIV patients with precancerous anal lesions.
Additional locations may be listed on ClinicalTrials.gov for NCT06626230.
Locations matching your search criteria
United States
Georgia
Atlanta
Grady Health SystemStatus: Active
Contact: Lisa C. Flowers
Phone: 404-251-8817
Emory University Hospital/Winship Cancer InstituteStatus: Active
Contact: Lisa C. Flowers
Phone: 404-251-8931
PRIMARY OBJECTIVE:
I. Determine the maximum tolerated dose (MTD) of curcumin intra-anal powder in people with HIV (PWH) every day for a 14-day treatment period.
SECONDARY OBJECTIVE:
I. Summarize safety and tolerability of curcumin intra-anal powder in PWH every day for a 14-day treatment period.
EXPLORATORY OBJECTIVE:
I. To determine whether curcumin intra-anal powder will induce p53 and lead to immune control.
OUTLINE: This is a dose-escalation study.
Patients receive curcumin intra-anally once daily (QD) for 14 days in the absence of unacceptable toxicity. Patients also undergo anoscopy, anal swab collection on study.
Lead OrganizationEmory University Hospital/Winship Cancer Institute
Principal InvestigatorLisa C. Flowers